Stock Track | Vir Biotech Soars 5.74% on Analyst Optimism Despite Mixed Earnings

Stock Track

Nov 01, 2024

Vir Biotechnology, Inc. (NASDAQ: VIR) saw its stock price soar 5.74% on Thursday, November 1st, following an analyst rating reaffirmation and the company's latest earnings report. The surge came despite Vir reporting a larger quarterly loss than expected.

In a report released on October 31st, TD Cowen analyst Phil Nadeau maintained a "Buy" rating on Vir Biotechnology shares, citing the company's strong pipeline and long-term growth prospects. This positive analyst signal appears to have outweighed concerns over Vir's mixed Q3 earnings results.

For the quarter ended January 1, Vir reported an adjusted loss of $1.56 per share, wider than analysts' expectations of a $1.05 per share loss. However, the company's revenue of $2.38 million, while down 9.8% year-over-year, still came in ahead of some estimates. Vir's shares have declined 24.5% so far this year but gained 1.5% in the latest quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1128359915"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128359915\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128359915?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-01 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128359915","market":"hk","top_or_hot":-1,"title":"Stock Track | Vir Biotech Soars 5.74% on Analyst Optimism Despite Mixed Earnings","media":"Stock Track","content":"<p>Vir Biotechnology, Inc. (NASDAQ: VIR) saw its stock price soar 5.74% on Thursday, November 1st, following an analyst rating reaffirmation and the company's latest earnings report. The surge came despite Vir reporting a larger quarterly loss than expected.\n\n<p>In a report released on October 31st, TD Cowen analyst Phil Nadeau maintained a \"Buy\" rating on Vir Biotechnology shares, citing the company's strong pipeline and long-term growth prospects. This positive analyst signal appears to have outweighed concerns over Vir's mixed Q3 earnings results.\n\n<p>For the quarter ended January 1, Vir reported an adjusted loss of $1.56 per share, wider than analysts' expectations of a $1.05 per share loss. However, the company's revenue of $2.38 million, while down 9.8% year-over-year, still came in ahead of some estimates. Vir's shares have declined 24.5% so far this year but gained 1.5% in the latest quarter.","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Vir Biotech Soars 5.74% on Analyst Optimism Despite Mixed Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Vir Biotech Soars 5.74% on Analyst Optimism Despite Mixed Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-01 21:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vir Biotechnology, Inc. (NASDAQ: VIR) saw its stock price soar 5.74% on Thursday, November 1st, following an analyst rating reaffirmation and the company's latest earnings report. The surge came despite Vir reporting a larger quarterly loss than expected.\n\n<p>In a report released on October 31st, TD Cowen analyst Phil Nadeau maintained a \"Buy\" rating on Vir Biotechnology shares, citing the company's strong pipeline and long-term growth prospects. This positive analyst signal appears to have outweighed concerns over Vir's mixed Q3 earnings results.\n\n<p>For the quarter ended January 1, Vir reported an adjusted loss of $1.56 per share, wider than analysts' expectations of a $1.05 per share loss. However, the company's revenue of $2.38 million, while down 9.8% year-over-year, still came in ahead of some estimates. Vir's shares have declined 24.5% so far this year but gained 1.5% in the latest quarter.\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIR","symbol_name":"Vir Biotechnology, Inc.","start_time":0,"source_url":"","article_id":"1128359915","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128359915","pubTimestamp":1730468399,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Vir Biotechnology, Inc.  saw its stock price soar 5.74% on Thursday, November 1st, following an analyst rating reaffirmation and the company's latest earnings report. The surge came despite Vir reporting a larger quarterly loss than expected.In a report released on October 31st, TD Cowen analyst Phil Nadeau maintained a \"Buy\" rating on Vir Biotechnology shares, citing the company's strong pipeline and long-term growth prospects. This positive analyst signal appears to have outweighed concerns ov","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"translate_title":"尽管盈利好坏参半，但分析师乐观情绪推动Vir Biotech股价飙升5.74%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":1},"content_text":"Vir Biotechnology, Inc. (NASDAQ: VIR) saw its stock price soar 5.74% on Thursday, November 1st, following an analyst rating reaffirmation and the company's latest earnings report. The surge came despite Vir reporting a larger quarterly loss than expected.\n\nIn a report released on October 31st, TD Cowen analyst Phil Nadeau maintained a \"Buy\" rating on Vir Biotechnology shares, citing the company's strong pipeline and long-term growth prospects. This positive analyst signal appears to have outweighed concerns over Vir's mixed Q3 earnings results.\n\nFor the quarter ended January 1, Vir reported an adjusted loss of $1.56 per share, wider than analysts' expectations of a $1.05 per share loss. However, the company's revenue of $2.38 million, while down 9.8% year-over-year, still came in ahead of some estimates. Vir's shares have declined 24.5% so far this year but gained 1.5% in the latest quarter.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}